摘要
目的:探讨伏诺拉生联合四联疗法在幽门螺杆菌(Hp)阳性慢性胃炎(CG)患者中的应用效果。方法:选取莆田学院附属医院2024年4—10月收治的Hp阳性CG患者98例,按随机数字表法分两组,各49例。对照组予四联疗法治疗,治疗组予伏诺拉生联合四联疗法治疗。对比两组的治疗效果、Hp转阴率、胃蛋白酶原水平、炎症指标、胃肠激素指标及不良反应。结果:治疗组总有效率(95.92%)、Hp转阴率(91.84%)较对照组(81.63%、75.51%)高(P<0.05);治疗组治疗2周后胃蛋白酶原Ⅰ(PGⅠ)、胃动素(MTL)、降钙素基因相关肽(CGRP)、IL-4水平较对照组高,胃蛋白酶原Ⅱ(PGⅡ)、胃泌素(GAS)、hs-CRP、IL-6、TNF-α水平较对照组低(P<0.05);治疗组与对照组不良反应发生率对比,差异无统计学意义(P>0.05)。结论:Hp阳性CG患者采用伏诺拉生联合四联疗法治疗的效果较好,可提高Hp转阴率,调节胃蛋白酶原水平,降低炎症指标,调节胃肠激素,且安全性好。
Objective:To explore the application effect of Fumarate combined with quadruple therapy in patients with Helicobacter pylori(Hp)positive chronic gastritis(CG).Method:A total of 98 patients with Hp positive CG admitted to Affiliated Hospital of Putian University from April to October 2024 were selected and divided into two groups using the random number table method,with 49 cases in each group.The control group was treated with quadruple therapy,while the treatment group was treated with Fumarate combined with quadruple therapy.The therapeutic effects,Hp conversion rate,pepsinogen levels,inflammatory indicators,gastrointestinal hormone indicators,and adverse reactions between two groups were compared.Result:The total effective rate(95.92%)and Hp conversion rate(91.84%)of the treatment group were higher than those of the control group(81.63%,75.51%)(P<0.05).The levels of pepsinogen Ⅰ(PGⅠ),motilin(MTL),calcitonin gene-related peptide(CGRP)and IL-4 in the treatment group were higher than those in the control group after 2 weeks of treatment,while the levels of pepsinogen Ⅱ(PGⅡ),gastrin(GAS),hs-CRP,IL-6 and TNF-α were lower than those in the control group(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the treatment group and the control group(P>0.05).Conclusion:The treatment of Hp positive CG patients with Fumarate combined with quadruple therapy has a better effect,which can improve the Hp conversion rate,regulate the levels of pepsinogen,reduce inflammatory indicators,regulate gastrointestinal hormones,and has good safety.
作者
蔡宝壤
CAI Baorang(Endoscopy Center,Affiliated Hospital of Putian University,Putian 351100,China)
出处
《中国医学创新》
2025年第22期68-72,共5页
Medical Innovation of China
关键词
慢性胃炎
幽门螺杆菌
伏诺拉生
四联疗法
胃蛋白酶原
炎症指标
Chronic gastritis
Helicobacter pylori
Fumarate
Quadruple therapy
Pepsinogen
Inflammatory indicators
作者简介
通信作者:蔡宝壤。
